• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Nov. 25, 2013

View Archived Issues

Regeneron’s Sarilumab Shines in RA; ‘Competitive’ to Actemra

Wall Street fell short of rejoicing when Regeneron Pharmaceuticals Inc. popped the lid off Phase III data with sarilumab that met all endpoints in rheumatoid arthritis (RA), and the firm’s chief scientific officer, George Yancopoulos, said he knows why. Read More

Editas Medicine Raises $43M for Genome ‘Debugging’ Technology

Flagship Ventures, Polaris Partners and Third Rock Ventures have teamed up to fund a biotech start-up based on a genome-editing platform to the tune of $43 million in Series A financing. Read More

Small Rebound for Ariad Stock on Positive CHMP Vote for Iclusig

Shares of Ariad Pharmaceuticals Inc. gained 35.5 percent Friday after the European Committee for Medicinal Products for Human Use (CHMP) recommended that leukemia drug Iclusig (ponatinib) remain on the market in Europe. Read More

Lawmakers Intent on Rescuing FDA Fees from Sequester

Lawmakers are leaving no stone unturned in their struggle to free FDA user fees from indiscriminate sequestration cuts. The latest effort was a letter, sent last week, asking congressional budget negotiators to clearly state in their final agreement Congress’ intent to spare all user fees from the sequester. Read More

Study Shows ApoE Variants Affect the Speed of Alzheimer’s

Variants in the ApoE gene are the strongest genetic risk factor there is for developing Alzheimer’s disease. Inheriting the E2 allele decreases the number of plaques, while inheriting the E4 allele increases the number of plaques and raises the risk of developing Alzheimer’s disease – for those unlucky individuals who have two copies, that risk jumps by 12-fold. E4 carriers also start developing the disease decades earlier than those with E2 alleles. Read More

Other News To Note

• Bavarian Nordic A/S, of Kvistgaard, Denmark, said Health Canada granted a notice of compliance approving Imvamune for active immunization against smallpox in a public health emergency. Read More

Stock Movers

Read More

Clinic Roundup

• Threshold Pharmaceuticals Inc., of South San Francisco, reported early data from a Phase I trial of TH-302 in combination with Avastin (bevacizumab, Roche AG) for recurrent glioblastoma. Read More

Bench Press: BioWorld Looks at Translational Medicine

Roughly a third of all tumors have mutations in the protein RAS, but attempts to drug the enzyme have so far been unsuccessful. Now, a team from the University of California at San Francisco has identified small molecules that can bind one particular mutant of KRAS. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 20, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 18, 2025.
  • Brain, syringe hovering over hands

    NICE rejects Lilly‘s Kisunla and Eisai‘s Leqembi

    BioWorld
    To no great surprise, the U.K.’s health technology assessment body has found that the benefits of the first two approved Alzheimer’s disease drugs are too small...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 17, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe